Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients

Zhong, Gang; Hk, Li; Shan, Tao; N, Zhang

doi:10.4238/2015.december.16.22

Cited by 5 publications

(5 citation statements)

References 20 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Bai et al 16 discovered that patients carrying the GT and TT genotypes of rs3212986 showed a significantly poorer response to chemotherapy than did those carrying the GG genotype. In contrast to them, Zhong et al’s 17 research showed no significant association between ERCC1 rs3212986 polymorphism and GC, which was consistent with our conclusions. Considering the reason, this may result from the complicated and multistep process and NER pathway factors might play an important role in functioning jointly to alter clinical outcome of GC.…”

Section: Discussionsupporting

confidence: 92%

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

Tang

Wang

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundA number of studies have investigated the roles of excision repair cross-complementation group 1 (ERCC1) gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore ERCC1 rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC.MethodsPubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between ERCC1 rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC. A fixed-effect or random-effect model was used to calculate the pooled odds ratios (ORs) based on the results from the heterogeneity tests.ResultsThe result revealed that there was no significant association between the ERCC1 rs3212986 A/C polymorphism and response to chemotherapy in GC under comparison models (AA + CA versus CC, OR 0.95, P=0.80, AA versus CA, OR 0.85, P=0.55, AA versus CC, OR 0.74, P=0.47). Further identification suggested that ERCC1 rs3212986 A/C polymorphisms were not linked with the overall survival of GC (AA + CA versus CC, OR 1.09, P=0.52, AA versus CA, OR 1.05, P=0.85, AA versus CC, OR 1.43, P=0.23).ConclusionOur meta-analysis indicated that the ERCC1 rs3212986 A/C polymorphism was not associated with response to chemotherapy or overall survival time in GC. Well-designed studies with larger sample sizes and more ethnic groups should be performed to further validate our results.

show abstract

Section: Discussionsupporting

confidence: 92%

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

Tang

Wang

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…1 Homozygous model (TT vs CC) . A total of 8 studies [ 12 – 15 , 19 , 21 , 24 , 34 ] involving 1569 patients were included in the homozygous model. There were 3 studies on ovarian cancer, 2 on osteosarcoma, 2 on gastric cancer, and 1 on esophageal cancer.…”

Section: Resultsmentioning

confidence: 99%

“…2 Heterozygous model (CT vs CC) . A total of 7 studies [ 12 , 13 , 15 , 19 , 21 , 24 , 34 ] involving 1360 patients were included in the homozygous model. Heterozygous model (CT vs CC): I 2 = 40.1%, fixed effect model was used, HR = 1.22, 95% CI (0.95,1.57), P = 0.115, as shown in Fig 11(E) .…”

Section: Resultsmentioning

confidence: 99%

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population

Lü

Jiang

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Platinum-based chemotherapy is one of the most common treatments for many cancers; however, the effect of chemotherapy varies from individual to individual. Excision repair cross complementation group 1 (ERCC1) is widely recognized as a key gene regulating nucleotide excision repair (NER) and is closely associated with platinum response. Many studies have yielded conflicting results regarding whether ERCC1 polymorphisms can affect the response to platinum and overall survival (OS). Therefore, it is necessary to perform a meta-analysis of patients with specific races and cancer types. Methods Eight databases (EMBASE, PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, Scopus, VIP, China Biology Medicine disc and Wanfang databases) were searched. Results were expressed in terms of odds ratios (ORs), hazard ratios (HRs) and 95% CIs. Results In this study, rs11615, rs2298881 and rs3212986 SNPs were studied. In the comparison between CT and TT on the response to platinum, esophageal cancer [I2 = 0%, OR = 6.18, 95% CI(1.89,20.23), P = 0.003] and ovarian cancer [I2 = 0%, OR = 4.94, 95% CI(2.21,11.04), P<0.001] showed that the rs11615 CT genotype predicted a better response. In the comparison between CC and TT, ovarian cancer [I2 = 48.0%, OR = 6.15, 95% CI (2.56,14.29), P<0.001] indicated that the CC genotype predicted a better response. In the meta-analysis of OS, the CC genotype was related to longer OS than TT in ovarian cancer [TT vs CC: I2 = 57.7%, HR = 1.71, 95% CI (1.18, 2.49), P<0.001]. Conclusion The ERCC1 rs11615 polymorphism was related to the response to platinum and OS, but the correlation is based on specific cancer types in the Asian population.

show abstract

“…ERCC1 protein is involved in the DNA damage incision process and ERCC2 in the damage unwinding process. Polymorphisms in ERCC1 and ERCC2 could alter the ability to repair DNA, thereby affecting the response or survival of cancer patients [ 65 ]. Two studies included in this review reported a significant association of the ERCC1 rs11615, ERCC1 rs10412761, and ERCC2 rs1799787 SNPs with response to neoadjuvant capecitabine-based chemoradiation in European ancestry patients (Spain, France) [ 24 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

Cura

Pérez-Ramírez

Sánchez-Martín

et al. 2023

Cancers

View full text Add to dashboard Cite

The aim of this systematic review was to provide a comprehensive overview of the literature published in the last decade on the association of single-nucleotide polymorphisms in genes involved in the pharmacodynamic and pharmacokinetic pathways of capecitabine with treatment outcomes among colorectal cancer patients. A systematic search of the literature published in the last 10 years was carried out in two databases (Medline and Scopus) using keywords related to the objective. Quality assessment of the studies included was performed using an assessment tool derived from the Strengthening the Reporting of Genetic Association (STREGA) statement. Thirteen studies were included in this systematic review. Genes involved in bioactivation, metabolism, transport, mechanism of action of capecitabine, DNA repair, and folate cycle were associated with toxicity. Meanwhile, genes related to DNA repair were associated with therapy effectiveness. This systematic review reveals that several SNPs other than the four DPYD variants that are screened in clinical practice could have an impact on treatment outcomes. These findings suggest the identification of future predictive biomarkers of effectiveness and toxicity in colorectal cancer patients treated with capecitabine. However, the evidence is sparse and requires further validation.

show abstract

Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients

Cited by 5 publications

References 20 publications

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

<em>ERCC1</em> rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

Contact Info

Product

Resources

About